Investigating how PDE2A affects mitochondrial function in Alzheimer's disease
Role of PDE2A in mitochondrial dysfunction in Alzheimer’s disease
This study is looking at how a specific enzyme called PDE2A affects brain cell health and energy production in people with Alzheimer's disease, with the hope of finding new ways to help improve memory and brain function.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-11080885 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of PDE2A, an enzyme that regulates important cellular functions, in the context of mitochondrial dysfunction associated with Alzheimer's disease. The study aims to explore how changes in PDE2A expression impact mitochondrial dynamics and the overall health of neurons in the brain. By examining brain samples from Alzheimer's patients and using animal models, researchers will investigate the molecular mechanisms that contribute to cognitive decline in this condition. The ultimate goal is to identify potential therapeutic targets that could improve mitochondrial function and cognitive outcomes for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those exhibiting early signs of cognitive decline.
Not a fit: Patients with other forms of dementia unrelated to Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that enhance cognitive function and slow the progression of Alzheimer's disease.
How similar studies have performed: Previous studies have shown promising results with PDE2A inhibitors in enhancing cognitive function, indicating that this approach may hold significant potential.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Xu, Ying — Rutgers Biomedical and Health Sciences
- Study coordinator: Xu, Ying
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.